These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9628224)

  • 21. Human immunodeficiency virus (HIV) type 1 transframe protein can restore activity to a dimerization-deficient HIV protease variant.
    Dautin N; Karimova G; Ladant D
    J Virol; 2003 Aug; 77(15):8216-26. PubMed ID: 12857890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitor binding to the Phe53Trp mutant of HIV-1 protease promotes conformational changes detectable by spectrofluorometry.
    Rodríguez EJ; Debouck C; Deckman IC; Abu-Soud H; Raushel FM; Meek TD
    Biochemistry; 1993 Apr; 32(14):3557-63. PubMed ID: 8466899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The p2gag peptide, AEAMSQVTNTATIM, processed from HIV-1 Pr55gag was found to be a suicide inhibitor of HIV-1 protease.
    Misumi S; Kudo A; Azuma R; Tomonaga M; Furuishi K; Shoji S
    Biochem Biophys Res Commun; 1997 Dec; 241(2):275-80. PubMed ID: 9425262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease.
    Ohtaka H; Velázquez-Campoy A; Xie D; Freire E
    Protein Sci; 2002 Aug; 11(8):1908-16. PubMed ID: 12142445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression and purification of active form of HIV-1 protease from E.coli.
    Wan M; Loh BN
    Biochem Mol Biol Int; 1995 Apr; 35(4):899-912. PubMed ID: 7627139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design of symmetry-based, peptidomimetic inhibitors of human immunodeficiency virus protease.
    Kempf DJ
    Methods Enzymol; 1994; 241():334-54. PubMed ID: 7854187
    [No Abstract]   [Full Text] [Related]  

  • 27. [HIV-1 proteinase mutant with an altered region of the active center].
    Dergousova NI; Rumsh LD; Andreeva NS
    Mol Biol (Mosk); 1998; 32(4):678-85. PubMed ID: 9785574
    [No Abstract]   [Full Text] [Related]  

  • 28. Inhibition of HIV protease activity by heterodimer formation.
    Babé LM; Pichuantes S; Craik CS
    Biochemistry; 1991 Jan; 30(1):106-11. PubMed ID: 1988010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.
    Friedler A; Blumenzweig I; Baraz L; Steinitz M; Kotler M; Gilon C
    J Mol Biol; 1999 Mar; 287(1):93-101. PubMed ID: 10074409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potent inhibition of drug-resistant HIV protease variants by monoclonal antibodies.
    Bartonová V; Král V; Sieglová I; Brynda J; Fábry M; Horejsí M; Kozísek M; Sasková KG; Konvalinka J; Sedlácek J; Rezácová P
    Antiviral Res; 2008 Jun; 78(3):275-7. PubMed ID: 18329737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Crucial amides for dimerization inhibitors of HIV-1 protease.
    Bowman MJ; Chmielewski J
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1395-8. PubMed ID: 15006369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-1 protease inhibitors containing statine: inhibitory potency and antiviral activity.
    Fehrentz JA; Chomier B; Bignon E; Venaud S; Chermann JC; Nisato D
    Biochem Biophys Res Commun; 1992 Oct; 188(2):865-72. PubMed ID: 1445327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel strategies for targeting the dimerization interface of HIV protease with cross-linked interfacial peptides.
    Bowman MJ; Chmielewski J
    Biopolymers; 2002; 66(2):126-33. PubMed ID: 12325162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sensitive genetic screen for protease activity based on a cyclic AMP signaling cascade in Escherichia coli.
    Dautin N; Karimova G; Ullmann A; Ladant D
    J Bacteriol; 2000 Dec; 182(24):7060-6. PubMed ID: 11092869
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cloning, expression and purification of a recombinant poly-histidine-linked HIV-1 protease.
    Leuthardt A; Roesel JL
    FEBS Lett; 1993 Jul; 326(1-3):275-80. PubMed ID: 8325379
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An efficient procedure for the expression and purification of HIV-1 protease from inclusion bodies.
    Nguyen HL; Nguyen TT; Vu QT; Le HT; Pham Y; Trinh PL; Bui TP; Phan TN
    Protein Expr Purif; 2015 Dec; 116():59-65. PubMed ID: 26231073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic binding of inhibitors to the protease from HIV type 1.
    Asante-Appiah E; Chan WW
    Biochem J; 1996 Apr; 315 ( Pt 1)(Pt 1):113-7. PubMed ID: 8670094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systematic profiling of substrate binding response to multidrug-resistant mutations in HIV-1 protease: Implication for combating drug resistance.
    Lv Y; Li J; Fang J; Jiao X; Yan L; Shan B
    J Mol Graph Model; 2017 Jun; 74():83-88. PubMed ID: 28371730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of HIV-1 replication by a peptide dimerization inhibitor of HIV-1 protease.
    Davis DA; Brown CA; Singer KE; Wang V; Kaufman J; Stahl SJ; Wingfield P; Maeda K; Harada S; Yoshimura K; Kosalaraksa P; Mitsuya H; Yarchoan R
    Antiviral Res; 2006 Nov; 72(2):89-99. PubMed ID: 16687179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Occupation of a thermoresistant-scaffold (αRep) at SP1-NC cleavage site disturbs the function of HIV-1 protease.
    Hadpech S; Peerakam N; Chupradit K; Tayapiwatana C
    Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32519747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.